MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
American Well Corporation Deferred Revenue 2011-2026 | AMWL
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue American Well Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.6 M | 53.2 M | 46.4 M | 49.5 M | 68.8 M | 66.7 M | 66.5 M | 64.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.8 M | 22.6 M | 54.7 M |
Quarterly Deferred Revenue American Well Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.5 M | 41.1 M | 57.4 M | 53.2 M | 62.5 M | 64.3 M | 59.1 M | 53.1 M | 60.2 M | 65.6 M | 49.5 M | 50.2 M | - | 68.8 M | 68.8 M | 60.9 M | 57.8 M | 63.2 M | 66.7 M | 66.7 M | 66.7 M | 66.7 M | 66.5 M | 66.5 M | - | - | 64.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 68.8 M | 29.5 M | 59.5 M |
Deferred Revenue of other stocks in the Health information services industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
531 M | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
8.68 M | - | 4.4 % | $ 133 M | USA |
 |
Change Healthcare
CHNG
|
469 M | - | - | $ 9.03 B | USA |
 |
Accolade
ACCD
|
25.9 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
6.85 M | - | -7.28 % | $ 227 M | USA |
 |
Inovalon Holdings, Inc.
INOV
|
10.9 M | - | - | $ 6.37 B | USA |
 |
Covetrus
CVET
|
28 M | - | - | $ 2.94 B | USA |
 |
Evolent Health
EVH
|
5.76 M | $ 2.64 | -1.31 % | $ 247 M | USA |
 |
HealthStream
HSTM
|
84.2 M | $ 19.91 | -1.24 % | $ 605 M | USA |
 |
Health Catalyst
HCAT
|
53.3 M | $ 1.84 | -7.54 % | $ 111 M | USA |
 |
iCAD
ICAD
|
3.86 M | - | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
569 K | - | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
326 M | - | -10.39 % | $ 886 M | USA |
 |
So-Young International
SY
|
135 M | $ 3.47 | -6.35 % | $ 275 M |  China |
 |
MTBC
MTBC
|
1.21 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
6.04 M | $ 2.17 | -2.91 % | $ 837 M | USA |
 |
Omnicell
OMCL
|
141 M | $ 36.4 | -3.75 % | $ 1.68 B | USA |
 |
OptimizeRx Corporation
OPRX
|
172 K | $ 8.0 | -13.33 % | $ 137 M | USA |
 |
1Life Healthcare
ONEM
|
47.9 M | - | - | $ 3.37 B | USA |
 |
Premier
PINC
|
22.5 M | - | - | $ 2.33 B | USA |
 |
Phreesia
PHR
|
24.1 M | $ 11.88 | -4.96 % | $ 648 M | USA |
 |
Zhongchao
ZCMD
|
6.76 K | $ 0.22 | -8.99 % | $ 1.15 M | China |
 |
R1 RCM
RCM
|
83.9 M | - | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
2.72 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
52.9 M | - | - | $ 1.6 B | USA |
 |
Schrödinger
SDGR
|
112 M | $ 11.39 | -4.97 % | $ 828 M | USA |
 |
Signify Health
SGFY
|
2.4 M | - | -0.02 % | $ 7.21 B | USA |
 |
10x Genomics
TXG
|
13.2 M | $ 17.63 | -7.94 % | $ 2.07 B | USA |
 |
Streamline Health Solutions
STRM
|
6.1 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
79.3 M | $ 4.44 | -5.13 % | $ 757 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
4.86 M | - | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
1.05 B | $ 172.07 | -2.81 % | $ 27.6 B | USA |
 |
SCWorx Corp.
WORX
|
354 K | $ 0.26 | 41.67 % | $ 379 K | USA |